Search

Your search keyword '"John D. Newell‐Price"' showing total 4 results
Start Over Author "John D. Newell‐Price"
4 results on '"John D. Newell‐Price"'

1. Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

Author

Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, Deborah L. Cooper, Juliana B. Drummond, Mark Gurnell, Miles Levy, Ann McCormack, John D. Newell-Price, Joseph G. Verbalis, and John Wass

Subjects
Medicine, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

“What's in a name? That which we call a rose / By any other name would smell as sweet” (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.

Published
2022
Full Text
View/download PDF

2. Quality of Life in Post-Surgical Hypoparathyroidism (PoSH) in Thyroid and Parathyroid Surgery

Author

Sarah L. Hillary, Je Ern Chooi, Jonathan Wadsley, John D. Newell-Price, Nicola J. Brown, and Saba P. Balasubramanian

Subjects
Aged, 80 and over, Male, Cross-Sectional Studies, Hypocalcemia, Hypoparathyroidism, Quality of Life, Thyroid Gland, Humans, Female, Surgery, Middle Aged, Fatigue, Aged
Abstract

Background Post-surgical hypoparathyroidism (PoSH) is often long term, with significant associated morbidity and ongoing treatment. A recent systematic review found impaired quality of life (QoL) in patients with PoSH, despite stable treatment. Most studies did not include an appropriate control arm and further studies were recommended, taking into account underlying disease and comorbidities. This study aims to compare QoL in patients with PoSH with appropriate control groups. Methods This was a cross-sectional observational study using the general quality of life SF-36 tool and a hypocalcaemia symptom score (HcSS) to assess QoL in patients with PoSH and controls (who had similar surgery but without PoSH). Participants were identified from two patient groups (the Butterfly Thyroid Cancer Trust and the Association for Multiple Endocrine Neoplasia Disorders) and a single tertiary centre in the UK. Results Four hundred and thirty-nine responses (female n = 379, PoSH n = 89) were included with a median (range) age of 52 (19–92) years. Reported dates of surgery ranged from 1973 to 2019. HcSS scores showed significantly more associated symptoms in patients with PoSH than those without (p p = 0.008) in the energy/fatigue subdomain of the SF-36. Conclusion Patients with PoSH reported significantly more fatigue and loss of energy compared to appropriately matched controls, but overall QoL was not significantly different. Standardised QoL measures may not be sensitive enough to highlight the impact on QoL in these patients. A disease-specific tool may be required.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results